-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa Therapeutics To Present Interim Clinical Results From The Ongoing Phase 1 Study Of The NEK7-Directed MGD MRT-8102 On Wednesday, January 7, at 8:00 a.m. ET

Benzinga·01/06/2026 21:11:23
Listen to the news

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.

A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.